{"publication_id":"f1c01d83-4fcb-4727-ae92-1f10f78503a4","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis","doi":"10.1186/s12916-025-04486-0","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","doi":"10.1038/s41591-025-03978-z","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)","doi":"10.1111/dom.70080","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis","doi":"10.1186/s40001-025-03124-y","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis","doi":"10.1002/edm2.70136","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial","doi":"10.2337/dc25-1080","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes","doi":"10.1001/jamacardio.2026.0245","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","doi":"10.3389/fcvm.2025.1731127","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials","doi":"10.1186/s12872-025-05278-3","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial","doi":"10.1038/s41591-026-04281-1","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial","doi":"10.1093/eurheartj/ehaf690","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )","doi":"10.1111/dom.70436","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease","doi":"10.1186/s40001-025-03241-8","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.","doi":"10.1016/j.eprac.2025.11.018","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials","doi":"10.3389/fmed.2026.1764664","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Abstract 4367243: Comparative Effects of Tirzepatide vs Semaglutide on 1-Year Mortality and Cardiovascular Outcomes in T2DM Patients with HFpEF","doi":"10.1161/circ.152.suppl_3.4367243","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"ADA 2024","doi":"10.2337/dc24-S006","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"WHO 2000","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"Ioannidis 2005","doi":"10.1371/journal.pmed.0020124","risk_of_bias":"not appraised in public sidecar","directness":"citation"}]}